AusperBio to Present AHB-137 Clinical Data in Late-Breaking Oral at AASLD 2024

AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd., collectively known as AusperBio, have announced that new clinical data from their primary candidate, AHB-137, an antisense oligonucleotide (ASO) therapeutic, will be featured in an oral presentation at the upcoming 2024 Liver Meeting®. This significant event is organized by the American Association for the Study of Liver Diseases (AASLD) and will take place from November 15-19, 2024, in San Diego, California.

AHB-137 is being developed with the aim of achieving a functional cure for chronic hepatitis B. The presentation will detail significant findings from ongoing clinical trials, emphasizing the potential of AHB-137 to significantly impact patient outcomes.

The presentation, titled "HBsAg loss and seroconversion in HBeAg-negative chronic hepatitis B subjects on NA therapy after AHB-137 treatment: preliminary data from an ongoing multicenter, randomized, open-label phase IIa study," will be part of the Late Breaking Abstract Parallel Session 2. The session will occur on November 18, 2024, from 5:00 pm to 6:30 pm PDT, with the presentation scheduled from 6:00 pm to 6:15 pm PDT. The authors of this key study include notable researchers such as Yanhua Ding, Xian Yu, Xieer Liang, Hong Ren, Chongyuan Xu, Wen Wang, Zhihong Liu, Yi Yang, Hong Zhang, Jinlin Hou, Shan Zhong, Hong Chen, Yilei Wen, Tingting Lu, Xiao Qiu, Lidan Wang, Di Zhao, Chen Yang, Miao Wang, Chris Yang, Guofeng Cheng, and Junqi Niu.

AHB-137, a unique unconjugated antisense oligonucleotide, was created using AusperBio's proprietary Med-Oligo™ ASO technology platform. This innovative therapeutic is aimed at treating chronic hepatitis B with the goal of achieving a functional cure. The preclinical and Phase 1 clinical data for AHB-137 were previously highlighted at the 2023 EASL™ conference and the 2024 EASL™ conference. Currently, AHB-137 is undergoing a Phase 1b trial at multiple international study sites and a concurrent Phase 2 trial in China. AusperBio's global development strategy is propelling AHB-137 rapidly towards the goal of curing HBV.

AusperBio is a clinical-stage biopharmaceutical company with operations in both the USA and China. The company is devoted to advancing oligonucleotide and targeted delivery technologies with the purpose of developing transformative therapies. Their initial focus is on curing chronic hepatitis B infection. AusperBio has developed a proprietary Med-Oligo™ ASO platform, which has shown to significantly enhance the current ASO therapeutics through novel insights into ASO design. By combining this with efficient targeted delivery conjugation technologies, the Med-Oligo™ Platform enables ASO therapeutics to address a wide variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.

The upcoming presentation at the 2024 Liver Meeting® is a pivotal moment for AusperBio, as it showcases the promising potential of AHB-137 and reflects the company's dedication to innovative treatments for chronic hepatitis B and other significant health challenges.